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Novel therapies resulting from regenerative medicine and tissue engineering technol-
ogy may offer new hope for patients with injuries, end-stage organ failure, or other clin-
ical issues. Currently, patients with diseased and injured organs are often treated with 
transplanted organs. However, there is a shortage of donor organs that is worsening 
yearly as the population ages and as the number of new cases of organ failure increases. 
Scientists in the field of regenerative medicine and tissue engineering are now applying 
the principles of cell transplantation, material science, and bioengineering to construct 
biological substitutes that can restore and maintain normal function in diseased and 
injured tissues. In addition, the stem cell field is a rapidly advancing part of re-
generative medicine, and new discoveries in this field create new options for this type 
of therapy. For example, new types of stem cells, such as amniotic fluid and placental 
stem cells that can circumvent the ethical issues associated with embryonic stem cells, 
have been discovered. The process of therapeutic cloning and the creation of induced 
pluripotent cells provide still other potential sources of stem cells for cell-based tissue 
engineering applications. Although stem cells are still in the research phase, some 
therapies arising from tissue engineering endeavors that make use of autologous, adult 
cells have already entered the clinical setting, indicating that regenerative medicine 
holds much promise for the future.
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INTRODUCTION
　Patients suffering from diseased and injured organs are 
often treated with transplanted organs, and this treatment 
has been in use for over 50 years. In 1955, the kidney be-
came the first entire organ to be replaced in a human, when 
Murray transplanted this organ between identical twins. 
Several years later, Murray performed an allogeneic kid-
ney transplant from a non-genetically identical patient in-
to another. This transplant, which overcame the immuno-
logic barrier, marked a new era in medicine and opened the 
door for use of transplantation as a means of therapy for 
different organ systems. 
　As modern medicine increases the human lifespan, the 
aging population grows, and the need for donor organs 
grows with it, because aging organs are generally more 
prone to failure. However, there is now a critical shortage 
of donor organs, and many patients in need of organs will 
die while waiting for transplants. In addition, even if an or-
gan becomes available, rejection of organs is still a major 
problem in transplant patients despite improvements in 
the methods used for immunosuppression following the 
transplant procedure. Even if rejection does not occur, the 
need for lifelong use of immunosuppressive medications 
leads to a number of complications in these patients.
　These problems have led physicians and scientists to 
look to new fields for alternatives to organ transplantation. 
In the 1960s, a natural evolution occurred in which re-
searchers began to combine new devices and materials sci-
ences with cell biology, and a new field that is now termed 
tissue engineering was born. As more scientists from differ-
ent fields came together with the common goal of tissue re-
placement, the field of tissue engineering became more for-
mally established. Tissue engineering is now defined as “an 
interdisciplinary field which applies the principles of en-
gineering and life sciences towards the development of bio-2
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logical substitutes that aim to maintain, restore or improve 
tissue function.”
1 Then, after the discovery of human stem 
cells by Thomson’s group in the early 1980s,
2 the field of 
stem cell biology took shape and suggested that it may one 
day be possible to obtain and use donor stem cells in tissue 
engineering strategies, or perhaps even reactivate endoge-
nous stem cells and use them to regenerate failing organs 
in adult patients. 
　The fields of stem cells, cell transplantation, and tissue 
engineering all have one unifying concept-the regeneration 
of living tissues and organs. Thus, in 1999, William Haseltine, 
then the Scientific Founder and Chief Executive Officer of 
Human Genome Sciences, coined the term regenerative 
medicine, in effect bringing all these areas under one defin-
ing field.
3
　In the past two decades, scientists have attempted to en-
gineer virtually every tissue of the human body. This ar-
ticle will review the basic techniques used in tissue en-
gineering and discuss some of the progress that has been 
achieved in this field.
THE BASIC COMPONENTS OF REGENERATIVE 
MEDICINE STRATEGIES
　The field of regenerative medicine encompasses various 
areas of technology, such as tissue engineering, stem cells, 
and cloning. Tissue engineering, one of the major areas of 
regenerative medicine, follows the principles of cell trans-
plantation, materials science, and engineering toward the 
development of biological substitutes that can restore and 
maintain normal function. Tissue engineering strategies 
generally fall into two categories: the use of acellular scaf-
folds, which depend on the body's natural ability to re-
generate for proper orientation and direction of new tissue 
growth, and the use of scaffolds seeded with cells. Acellular 
scaffolds are usually prepared by manufacturing artificial 
scaffolds or by removing cellular components from tissues 
via mechanical and chemical manipulation to produce acel-
lular, collagen-rich matrices.
4-7 These matrices tend to 
slowly degrade on implantation and are generally replaced 
by the extracellular matrix (ECM) proteins that are se-
creted by the in-growing cells. Cells can also be used for 
therapy via injection, either with carriers such as hydro-
gels or alone. 
1. Biomaterials for use in regenerative medicine 
　In the past, synthetic materials were introduced to re-
place or to rebuild diseased tissues or parts in the human 
body. The manufacture of new materials, such as tetra-
fluoroethylene (Teflon) and silicone, opened a new field of 
research that led to the development of a wide array of de-
vices that could be applied for human use. Although these 
devices could provide structural support or replacement, 
the functional component of the original tissue was not 
restored. However, studies in cell biology, molecular biol-
ogy, and biochemistry allowed a better understanding of 
the ECM and its interaction with cells in the tissues of the 
body, as well as interactions with growth factors and their 
ligands, and as a result, new biomaterials were designed 
with these interactions in mind. 
　In tissue engineering, biomaterials replicate the bio-
logical and mechanical function of the native ECM found 
in tissues in the body. Biomaterials provide a three-dimen-
sional space in which cells can attach, grow, and form new 
tissues with appropriate structure and function. They also 
allow for the delivery of cells and appropriate bioactive fac-
tors (e.g., cell adhesion peptides, growth factors) to desired 
sites in the body.
8 Because most mammalian cell types are 
anchorage-dependent and will die if no cell-adhesion sub-
strate is available, biomaterials provide this substrate 
while allowing delivery of cells with high loading efficiency. 
Biomaterials can also provide mechanical support against 
in vivo forces so that the predefined three-dimensional 
structure of a tissue-engineered organ is maintained dur-
ing tissue development. 
　The ideal biomaterial should be biodegradable and bio-
resorbable to support the replacement of normal tissue 
without inducing inflammation. Incompatible materials 
are destined for an inflammatory or foreign-body response 
that eventually leads to rejection or necrosis. Because bio-
materials provide temporary mechanical support while 
the cells undergo spatial reorganization into tissue, a prop-
erly chosen biomaterial should allow the engineered tissue 
to maintain sufficient mechanical integrity to support it-
self in early development, while in late development, it 
should have begun degradation such that it does not hinder 
further tissue growth.
8 The degradation products, if pro-
duced, should be removed from the body via metabolic path-
ways at an adequate rate to ensure that the concentration 
of these degradation products in the tissues remains at a 
tolerable level.
9 
　Generally, three classes of biomaterials have been uti-
lized for engineering tissues: naturally derived materials 
(e.g., collagen and alginate),
10-14 acellular tissue matrices 
(e.g., bladder submucosa and small intestinal submuco-
sa),
4-7 and synthetic polymers such as polyglycolic acid 
(PGA), polylactic acid (PLA), and poly (lactic-co-glycolic 
acid) (PLGA).
15-18 These classes of biomaterials have been 
tested with respect to their biocompatibility.
19,20 Naturally 
derived materials and acellular tissue matrices have the 
potential advantage of biological recognition. However, 
synthetic polymers can be produced reproducibly on a large 
scale with controlled properties such as strength, degrada-
tion rate, and microstructure. 
2. Cells for use in cell therapy and tissue engineering
　1) Native cells: When native cells are used for tissue en-
gineering, a small piece of donor tissue is dissociated into 
individual cells. These cells are expanded in culture and ei-
ther injected directly back into the host or attached to a sup-
port matrix and then reimplanted. The source of donor tis-
sue can be heterologous (such as bovine), allogeneic (same 
species, different individual), or autologous. The preferred 
cells to use are autologous cells, where a biopsy of tissue 3
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is obtained from the host, the cells are dissociated and ex-
panded in culture, and the expanded cells are implanted 
into the same host.
5,21-28 The use of autologous cells, al-
though it may cause an inflammatory response, avoids re-
jection, and thus the deleterious side effects of immuno-
suppressive medications can be avoided. 
　Ideally, both structural and functional tissue replace-
ment will occur with minimal complications when autolo-
gous native cells are used. However, one of the limitations 
of applying cell-based regenerative medicine techniques to 
organ replacement has been the inherent difficulty of grow-
ing specific cell types in large quantities. Even when some 
organs, such as the liver, have a high regenerative capacity 
in vivo, cell growth and expansion in vitro may be difficult. 
By studying the privileged sites for committed precursor 
cells in specific organs, as well as exploring the conditions 
that promote differentiation, one may be able to overcome 
the obstacles that limit cell expansion in vitro. For exam-
ple, urothelial cells could be grown in the laboratory setting 
in the past, but only with limited expansion. Several proto-
cols were developed over the past two decades that identi-
fied the undifferentiated cells and kept them undifferen-
tiated during their growth phase.
27,29,30-32 With the use of 
these methods of cell culture, it is now possible to expand 
a urothelial strain from a single specimen that initially cov-
ered a surface area of 1 cm
2 to one covering a surface area 
of 4,202 m
2 (the equivalent of one football field) within 8 
weeks.
27 These studies indicated that it should be possible 
to collect autologous bladder cells from human patients, ex-
pand them in culture, and return them to the donor in suffi-
cient quantities for reconstructive purposes.
27,30 Major ad-
vances have been achieved within the past decade on the 
possible expansion of a variety of primary human cells, 
with specific techniques that make the use of autologous 
cells for clinical application possible.
　Most current strategies for tissue engineering depend on 
a sample of autologous cells from the diseased organ of the 
host. However, for many patients with extensive end-stage 
organ failure, a tissue biopsy may not yield enough normal 
cells for expansion and transplantation. In other instances, 
primary autologous human cells cannot be expanded from 
a particular organ, such as the pancreas. In these sit-
uations, stem cells are envisioned as being an alternative 
source of cells from which the desired tissue can be derived. 
Stem cells can be derived from discarded human embryos 
(human embryonic stem cells), from fetal tissue, or from 
adult sources (bone marrow, fat, skin). 
3. Stem cells for use in tissue engineering
　1) Embryonic stem cells: Human embryonic stem (hES) 
cells exhibit two remarkable properties: the ability to pro-
liferate in an undifferentiated but pluripotent state (self- 
renewal), and the ability to differentiate into many speci-
alized cell types.
36 They can be isolated by aspirating the 
inner cell mass from the embryo during the blastocyst stage 
(5 days post-fertilization) and are usually grown on feeder 
layers consisting of mouse embryonic fibroblasts or human 
feeder cells.
37 More recent reports have shown that these 
cells can be grown without the use of a feeder layer
38 and 
thus avoid the exposure of these human cells to mouse vi-
ruses and proteins. These cells have demonstrated lon-
gevity in culture by maintaining their undifferentiated 
state for at least 80 passages when grown by use of current 
published protocols.
2,39 In addition, hES cells are able to dif-
ferentiate into cells from all three embryonic germ layers 
in vitro. Skin and neurons have been formed, indicating ec-
todermal differentiation.
40-43 Blood, cardiac cells, cartilage, 
endothelial cells, and muscle have been formed, indicating 
mesodermal differentiation.
44-46 Pancreatic cells have been 
formed, indicating endodermal differentiation.
47 In addi-
tion, as further evidence of their pluripotency, embryonic 
stem cells can form embryoid bodies, which are cell ag-
gregations that contain all three embryonic germ layers 
while in culture and can form teratomas in vivo.
48 However, 
there are many ethical and religious concerns associated 
with hES cells because embryos are destroyed in order to 
obtain them. Thus, the use of these cells is currently banned 
in many countries.
　2) Stem cells from somatic cell nuclear transfer: Stem 
cells for tissue engineering could also be generated through 
cloning procedures. There has been tremendous interest in 
the field of nuclear cloning since the birth of the cloned 
sheep Dolly in 1997, but actually, Dolly was not the first 
animal produced by using nuclear transfer. In fact, frogs 
were the first successfully cloned vertebrates derived from 
nuclear transfer.
49 However, in the frog experiment, the 
nuclei used for cloning were derived from non-adult sources. 
In fact, live lambs were produced in 1996 by using nuclear 
transfer as well, but they were produced from differen-
tiated epithelial cells derived from embryonic discs.
50 The 
significance of Dolly was that she was the first mammal to 
be derived from an adult somatic cell by use of nuclear 
transfer.
51 Since then, animals from several species have 
been grown by using nuclear transfer technology, inclu-
ding cattle,
52 goats,
53 mice,
54 and pigs.
55-56
　Two types of nuclear cloning, reproductive cloning and 
therapeutic cloning, have been described, and a better un-
derstanding of the differences between the two types may 
help to alleviate some of the controversy that surrounds 
these technologies.
57-58 Banned in most countries for hu-
man applications, reproductive cloning is used to generate 
an embryo that has the identical genetic material as its cell 
source. This embryo can then be implanted into the uterus 
of a female to give rise to an infant that is a clone of the 
donor. On the other hand, therapeutic cloning is used to 
generate early stage embryos that are explanted in culture 
to produce embryonic stem cell lines whose genetic materi-
al is identical to that of its source. These autologous stem 
cells have the potential to become almost any type of cell 
in the adult body, and thus would be useful in tissue and 
organ replacement applications.
59 Therefore, therapeutic 
cloning, which has also been called somatic cell nuclear 
transfer, may provide an alternative source of transplan-
table cells. According to data from the Centers for Disease 4
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Control and Prevention, an estimated 3,000 Americans die 
every day of diseases that could have been treated with 
stem cell–derived tissues.
60-61 With current allogeneic tis-
sue transplantation protocols, rejection is a frequent com-
plication because of immunologic incompatibility, and im-
munosuppressive drugs are usually required.
59 The use of 
transplantable tissue and organs derived from therapeutic 
cloning could lead to the avoidance of immune responses 
that typically are associated with transplantation of non- 
autologous tissues.
60
　While promising, somatic cell nuclear transfer technol-
ogy has certain limitations that require further study be-
fore this technique can be applied widely in tissue or organ 
replacement therapy. First, the efficiency of the cloning 
process is very low, as evidenced by the fact that most em-
bryos derived from the cloning process do not survive.
62-64 
To improve cloning efficiency, further improvements are 
required in many of the complex steps of nuclear transfer, 
such as the enucleation process for oocytes, the actual 
transfer of a nucleus to this enucleated oocyte, and the acti-
vation process that instructs the cloned oocytes to begin 
dividing. In addition, cell cycle synchronization between 
donor cells and recipient oocytes must be accomplished.
65
　3) Reprogramming and generation of iPS cells: Within 
the past few years, exciting reports of the successful trans-
formation of adult somatic cells into pluripotent stem cells 
through genetic “reprogramming” have been published. 
Reprogramming is a technique that involves de-differen-
tiation of adult somatic cells (such as fibroblasts) to produce 
patient-specific pluripotent stem cells. This process is es-
pecially exciting because it allows pluripotent stem cells to 
be obtained without the use of embryos. Also, cells genera-
ted by reprogramming are genetically identical to the so-
matic cells used (and thus to the patient who donated these 
cells) and should not be rejected. Yamanaka was the first 
to discover that mouse embryonic fibroblasts (MEFs) and 
adult mouse fibroblasts could be reprogrammed into an 
“induced pluripotent state (iPS).”
66 They examined 24 
genes that were thought to be important for embryonic 
stem cells and identified 4 key genes that, when introduced 
into the reporter fibroblasts via retroviral vectors, resulted 
in drug-resistant cells. These were Oct3/4, Sox2, c-Myc, 
and Klf4. The resultant iPS cells possessed the immortal 
growth characteristics of self-renewing embryonic stem 
cells, expressed genes specific for embryonic stem cells, and 
generated embryoid bodies in vitro and teratomas in vivo. 
When iPS cells were injected into mouse blastocysts, they 
contributed to a variety of cell types. However, although 
iPS cells selected in this way were pluripotent, they were 
not identical to embryonic stem cells. Unlike embryonic 
stem cells, chimeras made from iPS cells did not result in 
full-term pregnancies. Gene expression profiles of the iPS 
cells showed that they possessed a distinct gene expression 
signature that was different from that of embryonic stem 
cells. In addition, the epigenetic state of the iPS cells was 
somewhere between that found in somatic cells and that 
found in embryonic stem cells, suggesting that the re-
programming was incomplete. 
　These results were improved significantly by Wernig 
and Jaenisch in July 2007.
67 Fibroblasts were infected with 
retroviral vectors and selected for the activation of endoge-
nous Oct4 or Nanog genes. Results from this study showed 
that DNA methylation, gene expression profiles, and the 
chromatin state of the reprogrammed cells were similar to 
those of embryonic stem cells. Teratomas induced by these 
cells contained differentiated cell types representing all 
three embryonic germ layers. Most importantly, the re-
programmed cells from this experiment could form viable 
chimeras and contribute to the germline-like embryonic 
stem cells, suggesting that these iPS cells were completely 
reprogrammed. Wernig et al observed that the number of 
reprogrammed colonies increased when drug selection was 
initiated later (day 20 rather than day 3 post-transduc-
tion). This suggests that reprogramming is a slow and grad-
ual process and may explain why previous attempts re-
sulted in incomplete reprogramming. 
　It has recently been shown that reprogramming of hu-
man cells is possible.
68-69 Yamanaka generated human iPS 
cells that are similar to hES cells in terms of morphology, 
proliferation, gene expression, surface markers, and ter-
atoma formation. Thompson’s group showed that retro-
viral transduction of the stem cell markers OCT4, SOX2, 
NANOG, and LIN28 could generate pluripotent stem cells. 
However, in both studies, the human iPS cells were similar 
but not identical to hES cells. Although reprogramming is 
an exciting phenomenon, our limited understanding of the 
mechanism underlying it currently limits the clinical ap-
plicability of the technique, but the future potential of re-
programming is quite exciting.
　4) Amniotic fluid and placental stem cells: An alternate 
source of stem cells is the amniotic fluid and placenta. 
Amniotic fluid and the placenta are known to contain mul-
tiple partially differentiated cell types derived from the de-
veloping fetus. We isolated stem cell populations from these 
sources, called amniotic fluid and placental stem cells 
(AFPSC), that express embryonic and adult stem cell mar-
kers.
70 The undifferentiated stem cells expand extensively 
without feeders and double every 36 hours. Unlike hES 
cells, the AFPSC do not form tumors in vivo. Lines main-
tained for over 250 population doublings retained long telo-
meres and a normal karyotype. AFS cells are broadly multi-
potent. Clonal human lines verified by retroviral marking 
can be induced to differentiate into cell types representing 
each embryonic germ layer, including cells of adipogenic, 
osteogenic, myogenic, endothelial, neuronal, and hepatic 
lineages. In this respect, they meet a commonly accepted 
criterion for pluripotent stem cells, without implying that 
they can generate every adult tissue. Examples of differen-
tiated cells derived from AFS cells and displaying speciali-
zed functions include neuronal lineage cells secreting the 
neurotransmitter L-glutamate or expressing G-protein- 
gated inwardly rectifying potassium (GIRK) channels, 
hepatic lineage cells producing urea, and osteogenic line-
age cells forming tissue engineered bone. The cells could 5
Jennifer L. Olson, et al
be obtained either from amniocentesis or chorionic villous 
sampling in the developing fetus, or from the placenta at 
the time of birth. The cells could be preserved for self-use 
and used without rejection, or they could be banked. A bank 
of 100,000 specimens could potentially supply 99% of the 
US population with a perfect genetic match for transplan-
tation. Such a bank may be easier to create than with other 
cell sources, because there are approximately 4.5 million 
births per year in the USA.
70
　5) Adult stem cells: Adult stem cells, especially hemato-
poietic stem cells, are the best understood cell type in stem 
cell biology.
71 The presence of stem cells in the adult was 
first discerned by Till and McCulloch, who were investigat-
ing the mechanisms by which the bone marrow could re-
generate after exposure to radiation.
72 However, adult stem 
cell research remains an area of intense study, because 
their potential for therapy may be applicable to a myriad 
of degenerative disorders. Within the past decade, adult 
stem cell populations have been found in many adult ti-
ssues other than the bone marrow and the gastrointestinal 
tract, including the brain,
73-74 skin,
75 and muscle.
76 Many 
other types of adult stem cells have been identified in or-
gans all over the body and are thought to serve as the pri-
mary repair entities for their corresponding organs.
77 The 
discovery of such tissue-specific progenitors has opened up 
new avenues for research.
　A notable exception to the tissue-specificity of adult stem 
cells is the mesenchymal stem cell (MSC), also known as 
the multipotent adult progenitor cell. This cell type is de-
rived from bone marrow stroma.
78-79 Such cells can differ-
entiate in vitro into numerous tissue types
80-81 and can also 
differentiate developmentally if injected into a blastocyst. 
Multipotent adult progenitor cells can develop into a variety 
of tissues including neuronal,
82 adipose,
76 muscle,
76,83 li-
ver,
84-85 lungs,
86 spleen,
87 and gut tissue,
79 but notably not 
bone marrow or gonads. 
　In addition, stem cells derived from adipose tissue may 
also be an autologous and self-renewing cell source. Adi-
pose-derived stem cells (ADSCs) have been shown to diffe-
rentiate into a variety of cell phenotypes, and since they are 
easily obtained, they show great promise for future types 
of reconstructive surgery based on tissue engineering and 
there have been several clinical trials using these cells. 
Wilson and Mizuno have both provided excellent, detailed 
reviews of these.
88-89 
　Research into more differentiated types of adult stem 
cells has, however, progressed slowly, mainly because in-
vestigators have had great difficulty in maintaining adult 
non-mesenchymal stem cells in culture. Some cells, such 
as those of the liver, pancreas, and nerve, have very low pro-
liferative capacity in vitro, and the functionality of some 
cell types is reduced after the cells are cultivated. Isolation 
of cells has also been problematic, because stem cells are 
present in extremely low numbers in adult tissue.
84,90 While 
the clinical utility of adult stem cells is currently limited, 
great potential exists for future use of such cells in tissue- 
specific regenerative therapies. The advantage of adult 
stem cells is that they can be used in autologous therapies, 
thus avoiding any complications associated with immune 
rejection.
CELLULAR THERAPIES
　The simplest regenerative medicine strategies are those 
that are based on the actions of cells, which can be implanted 
either alone or within a type of carrier material, such as a 
hydrogel. These cell therapies are designed to inject or im-
plant healthy cells to replace populations of cells that are 
no longer functioning properly owing to disease or injury. 
The cells used in these therapies can be autologous cells de-
rived from a tissue biopsy and expanded in culture, or they 
can be stem cells from various sources that can be guided 
to differentiate into appropriate cell types by using both en-
dogenous and exogenous biochemical cues.
　For example, one area of intense study in regenerative 
medicine is the pancreas, because the ability to replace or 
regenerate the insulin-producing cells of this organ could 
lead to novel treatments or a cure for diabetes. In a series 
of exciting experiments, Zhou et al demonstrated that re-
generation of the insulin-producing cells of the pancreas, 
the β-cells, may be possible by using cellular reprogram-
ming techniques
91 Using a mouse model, they showed that 
in vivo activation of a specific combination of three tran-
scription factors (Ngn3, Pdx1, and Mafa) by use of adeno-
viral vectors led to the reprogramming of adult differ-
entiated pancreatic exocrine cells into cells that closely re-
sembled β-cells. These cells were similar to native β-cells 
in size, shape, and ultrastructure, and they expressed genes 
that are specific to β-cells as well. Interestingly, these cells 
secreted insulin and expressed vascular endothelial growth 
factor (VEGF), which allowed them to remodel the local 
vasculature in a manner similar to native β-cells. In fact, 
these reprogrammed cells were able to partially ameliorate 
hyperglycemia in diabetic mice, suggesting that repro-
gramming techniques for treating disease may one day be-
come a reality.
　Degenerative muscle diseases such as Duchenne’s mus-
cular dystrophy have devastating effects on quality of life. 
To date, these genetic disorders have no suitable treat-
ment. Early enthusiasm for gene therapy interventions 
has been tempered by issues of vector toxicity and inade-
quate gene transfer to target muscle cells in vivo. However, 
natural mechanisms of muscle repair have suggested that 
cell-based therapy could take advantage of natural homing 
mechanisms to direct cells to the proper location.
92 Experi-
ments using the mdx mouse model, in which the dystrophin 
gene is mutated, indicate that injection of normal muscle 
precursors and dermal fibroblasts into skeletal muscle can 
lead to increased expression of dystrophin and improved 
functional outcomes. However, this treatment option re-
quires further studies before it can be widely applied in the 
clinic.
　Although many of these cell therapies are still in the ex-
perimental stage, some are being translated to the clinic 6
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and clinical trials are being performed. Vesicoureteral re-
flux (VUR; a condition in which urine flows backwards from 
the bladder into the ureter and kidney) and stress urinary 
incontinence are two urologic conditions that can result 
from dysfunction of a specific sphincter muscle. When se-
vere, these conditions are repaired surgically. However, 
cell-based therapies for both VUR and incontinence would 
be an important alternative to surgical repair of these 
conditions. Ideally, such a therapy would be easily ad-
ministered by injection and well tolerated by the patient. 
The injectable therapy should be non-antigenic, non-mi-
gratory, volume stable, and safe for human use, and in addi-
tion, it should be able to carry cells and serve as a matrix 
in vivo. 
　Toward this goal, long-term studies were conducted to 
determine the effects of injectable chondrocytes for the 
treatment of VUR in vivo.
93 Chondrocytes were chosen be-
cause the use of autologous cartilage for the treatment of 
VUR in humans would satisfy all of the requirements for 
an ideal injectable cell-based therapy. Chondrocytes de-
rived from an ear biopsy can be readily grown and expanded 
in culture. Neocartilage formation can be achieved in vitro 
and in vivo by using chondrocytes cultured on synthetic bio-
degradable polymers. In the VUR experiments, chon-
drocytes were suspended in an alginate matrix and injected 
around the vesicoureteral sphincter. In time, normal carti-
lage replaced the alginate as the alginate slowly degraded. 
This system was then adapted for the treatment of VUR in 
a porcine model.
94 These studies show that chondrocytes 
can be easily harvested and combined with alginate in vi-
tro, that the suspension can be easily injected cystoscopi-
cally, and that the elastic cartilage tissue formed can cor-
rect the VUR without any evidence of obstruction. 
　Two multicenter clinical trials were conducted by use of 
this engineered chondrocyte technology. First, patients 
with VUR were treated at 10 centers throughout the United 
States. The patients had a similar success rate as with oth-
er injectable substances in terms of cure. Cartilage for-
mation was not noted in patients with treatment failure. 
Patients who were cured probably had a biocompatible re-
gion of engineered autologous tissue present.
95 Secondly, 
patients with urinary incontinence were treated endo-
scopically with injected chondrocytes at three different 
medical centers. Phase 1 trials showed an approximate 
success rate of 80% at 3 and 12 months postoperatively.
96 
TISSUE THERAPIES
　Tissue engineering strategies are often referred to as 
“growing organs in the laboratory.” In these strategies, dif-
ferentiated cells or stem cells are seeded onto a biomaterial 
scaffold and this construct is allowed to mature in vitro in 
a bioreactor for a short time before implantation in vivo. 
These constructs are designed to replace a malfunctioning 
organ in its entirety. In recent years, it has been shown that 
hollow organs, such as the urinary bladder, urethra, and 
blood vessels, can be successfully engineered in the labo-
ratory, and these successes are described below. 
　The urethra can be repaired by using tissue-engineered 
grafts in several ways. It has been shown that various bio-
materials without cells, such as PGA and acellular colla-
gen-based matrices from small intestine and bladder, can 
be used experimentally (in animal models) for the regene-
ration of urethral tissue.
7,97-99 Acellular collagen matrices 
derived from bladder submucosa have been used experi-
mentally and clinically. In animal studies, segments of the 
urethra were resected and replaced with acellular matrix 
grafts in an onlay fashion. Histological examination showed 
complete epithelialization and progressive vessel and mu-
scle infiltration, and the animals were able to void through 
the neo-urethras.
7 These results were confirmed in a clini-
cal study of patients with hypospadias and urethral stric-
ture disease.
100 Decellularized cadaveric bladder submu-
cosa was used as an onlay matrix for urethral repair in pa-
tients with stricture disease and hypospadias. Patent, 
functional neo-urethras were noted in these patients with 
up to a 7-year follow-up. The use of an off-the-shelf matrix 
appears to be beneficial for patients with abnormal ure-
thral conditions and obviates the need for obtaining autolo-
gous grafts, thus decreasing operative time and eliminat-
ing donor site morbidity. 
　Unfortunately, the above techniques are not applicable 
for tubularized urethral repairs. The collagen matrices are 
able to replace urethral segments only when used in an on-
lay fashion. However, if a tubularized repair is needed, the 
collagen matrices should be seeded with autologous cells 
to avoid the risk of stricture formation and poor tissue 
development.
101 In addition, cell-seeded matrices must be 
used if the segment of urethra to be replaced is longer than 
about 1 cm.
102 Recently, Raya-Rivera and colleagues used 
tissue-engineered urethras that had been created from pa-
tients' own cells for tubularized urethral reconstruction. In 
this preliminary study, five boys who had urethral defects 
were treated. A tissue biopsy was taken from each patient, 
and the muscle and epithelial cells derived from the biopsy 
sample were expanded and seeded onto tubularized poly-
glycolic acid:poly(lactide-co-glycolide acid) scaffolds to cre-
ate neo-urethras for implantation. The patients then un-
derwent urethral reconstruction with the engineered 
urethras. After surgery, these patients were followed for 
up to 6 years. All of the patients experienced an increase 
in urinary flow rate, and serial radiographic and endo-
scopic studies showed that they maintained wide urethral 
calibers throughout the follow-up period and did not develop 
strictures. In addition, urethral biopsies were performed 
in these patients, and these revealed that by 3 months post- 
surgery, the engineered grafts had developed a normal 
appearing tissue architecture consisting of a urothelial layer 
surrounded by a muscular layer.
103
　In addition, similar techniques have been used to create 
tissue-engineered bladder constructs. Urothelial and mu-
scle cells can be expanded in vitro, seeded onto polymer 
scaffolds, and allowed to attach and form sheets of cells.
104 
These principles were applied in several studies in which 7
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tissue-engineered bladders were used to repair subtotal 
cystectomies in beagle dogs.
28,105-106 The first clinical ex-
perience in which engineered bladder tissue for cystoplasty 
reconstruction in patients was conducted starting in 1999. 
A small pilot study of seven patients was reported, using 
a collagen scaffold seeded with cells either with or without 
omentum coverage, or a combined PGA-collagen scaffold 
seeded with cells and omental coverage. The patients re-
constructed with the engineered bladder tissue created 
with the PGA-collagen cell-seeded scaffolds showed in-
creased compliance, decreased end-filling pressures, in-
creased capacities, and longer dry periods.
107 Although the 
experience is promising in terms of showing that engi-
neered tissues can be implanted safely, it is just a start in 
terms of accomplishing the goal of engineering fully func-
tional bladders. Further experimental and clinical work is 
being conducted. 
　Xenogenic or synthetic materials have been used as re-
placement blood vessels for complex cardiovascular lesions. 
However, these materials typically lack growth potential, 
and may place the recipient at risk for complications such 
as stenosis, thromboembolization, or infection.
108 Tissue- 
engineered vascular grafts have been constructed by using 
autologous cells and biodegradable scaffolds and have been 
applied in dog and lamb models.
109-112 The key advantage 
of using these autografts is that they degrade in vivo and 
thus allow the new tissue to form without the long-term 
presence of foreign material.
108 Translation of these techni-
ques from the laboratory to the clinical setting has begun, 
with autologous vascular cells harvested, expanded, and 
seeded onto a biodegradable scaffold.
113 The resultant auto-
logous construct was used to replace a stenosed pulmonary 
artery that had been previously repaired. Seven months af-
ter implantation, no evidence of graft occlusion or aneur-
ysmal changes was noted in the recipient. In addition, an-
other group created tissue-engineered blood vessels by us-
ing the cell-sheet multilayer method and then used these 
constructs to successfully create vascular access points for 
hemodialysis in 10 patients.
114 More recently, the same 
group completed a larger study on these engineered vessels 
for hemodialysis, which indicated that the 1-month and 
6-month patency of the grafts was 78% and 60%, respec-
tively, which meets the approved criteria for a high-risk pa-
tient cohort.
115
　Finally, few treatment options are currently available 
for patients who suffer from severe congenital tracheal pa-
thology, such as stenosis, atresia, and agenesis, due to the 
limited availability of autologous transplantable tissue in 
the neonatal period. Tissue engineering in the fetal period 
may be a viable alternative for the surgical treatment of 
these prenatally diagnosed congenital anomalies, because 
cells could be harvested and grown into transplantable ti-
ssue in parallel with the remainder of gestation. Chondro-
cytes from both elastic and hyaline cartilage specimens have 
been harvested from fetal lambs, expanded in vitro, and 
then dynamically seeded onto biodegradable scaffolds.
116 
The constructs were then implanted as replacement tra-
cheal tissue in fetal lambs. The resultant tissue-engineered 
cartilage was noted to undergo engraftment and epithelial-
ization, while maintaining its structural support and pa-
tency.
　Recently, Martin Birchall’s group moved this technology 
into a human patient with end-stage airway disease.
117 This 
group was able to remove the cellular material and MHC 
antigens from a human donor trachea and, using a speci-
alized bioreactor, seed this acellular matrix with chon-
drocytes and epithelial cells derived from the patient to re-
ceive the graft. This construct was then used to replace the 
patient’s left main bronchus. There were no perioperative 
complications, and the left lung ventilated normally as 
soon as the graft was placed. At 3 months after surgery, the 
patient’s lung function was in the normal range for her age 
and sex, and she was able to function normally. Although 
longer follow-up and larger study populations are needed, 
this report indicates that tissue engineering may be a new 
option for patients with airway disease.
　However, whereas there has been exciting progress with 
tissue engineering techniques for hollow organs, the develop-
ment of methods to generate larger, solid organs with more 
complex histological structure has been much more diffi-
cult. A number of issues must be addressed before fully func-
tional, engineered organs such as liver and kidney can be 
prepared in the laboratory. First, these organs contain ex-
tremely complex internal structures made up of numerous 
cell types arranged in very specific ways, and simple cell- 
seeding techniques may not be sufficient for reconstructing 
these structures. In addition, the large size of these organs 
dictates that the delivery of oxygen and nutrients to each 
part of the organ will be a challenge, unless a method for 
engineering a functional vascular network within the or-
gan can be found. However, despite the challenges, there 
have been some encouraging results from several studies. 
For example, the kidney contains multiple cell types and 
a complex functional anatomy that renders it one of the 
most difficult to reconstruct,
21,118 yet we were able to create 
a rudimentary form of this organ that appeared to have at 
least the filtration properties of the native kidney. 
　We applied the principles of both tissue engineering and 
therapeutic cloning in an effort to produce genetically iden-
tical renal tissue in a large animal model, the cow (Bos tau-
rus).
119 Bovine skin fibroblasts from adult Holstein steers 
were obtained by ear notch, and single donor cells were iso-
lated and microinjected into the perivitelline space of donor 
enucleated oocytes (nuclear transfer). The resulting blas-
tocysts were implanted into progestin-synchronized recip-
ients to allow for further in vivo growth. After 12 weeks, 
cloned renal cells were harvested and expanded in vitro. 
Next, the cloned renal cells were seeded on scaffolds con-
sisting of three collagen-coated cylindrical silastic cathe-
ters. The ends of the three membranes of each scaffold were 
connected to catheters that terminated into a collecting 
reservoir. This created a renal neo-organ with a mecha-
nism for collecting the excreted urinary fluid. These scaf-
folds with the collecting devices were transplanted sub-8
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cutaneously into the same steer from which the genetic ma-
terial originated and then retrieved 12 weeks after implan-
tation. 
　At this time, a yellow urine-like fluid was observed col-
lecting within the reservoir of the device. Chemical analysis 
of this fluid, including urea nitrogen and creatinine levels, 
electrolyte levels, specific gravity, and glucose concentra-
tion, revealed that the implanted renal cells possessed fil-
tration, reabsorption, and secretory capabilities. Histolo-
gical examination of the retrieved implants revealed exten-
sive vascularization and self-organization of the cells into 
glomeruli and tubule-like structures. A clear continuity be-
tween the glomeruli, the tubules, and the silastic catheter 
was noted that allowed the passage of urine into the collect-
ing reservoir. These studies demonstrated that cells de-
rived from nuclear transfer can be successfully harvested, 
expanded in culture, and transplanted in vivo with the use 
of biodegradable scaffolds on which the single suspended 
cells can organize into tissue structures that are geneti-
cally identical to those of the host. These studies were the 
first demonstration of the use of therapeutic cloning for re-
generation of tissues in vivo. However, the size of this de-
vice was small, and the challenge will be to create a larger 
device with functioning vasculature and innervations, so 
that it can replace all of the myriad metabolic functions of 
the kidney.
CHALLENGES AND FUTURE DIRECTIONS IN 
REGENERATIVE MEDICINE: TRANSLATING 
REGENERATIVE THERAPIES TO THE CLINIC
　The experiences with urethral, bladder, blood vessel, and 
tracheal replacement using tissue engineering provide en-
couragement for future efforts to engineer other organs in 
the laboratory. These experiences also cast light on unsolved 
problems. For example, innervation of tissues and organs 
is important for achieving full functionality. In the canine 
engineered bladder experiments, the observation of posi-
tive S-100 staining was consistent with growth of neural 
structures into the neo-bladders, and bladder function was 
restored soon after implantation.
28 Innervation of tissue- 
engineered constructs has been observed in other systems 
such as the small intestine.
120 Not only is successful con-
nection with the nervous system important for the func-
tionality of neo-organs, but evidence suggests that it can 
enhance tissue regeneration.
121-122 The controlled release 
of neurotrophic factors is one potential approach to promote 
peripheral nerve regeneration and synapse formation with 
engineered tissue.
123 Direct electrical stimulation has pro-
ven useful in muscle regeneration
124 and may have broader 
applicability.
　An even more fundamental issue for the ultimate success 
of laboratory-grown organs, particularly those with com-
plex three-dimensional structure, is the provision of ade-
quate oxygen and the generation of new vasculature. It has 
been appreciated for some years that in metabolically ac-
tive tissues, the distance over which oxygen typically must 
diffuse from a capillary bed to reach a cell is about 0.1 mm, 
but that in clinical grafts, the distance from the edge to the 
center of the graft is likely to exceed that by at least 50- 
fold.
125-126 Therefore, with few exceptions (e.g., cartilage), 
oxygen is rate-limiting for the viability of grafted cells, and 
thus for organ engineering. Neovascularization, an intri-
cate morphogenetic process that allows the formation of ex-
tensively branched vessels, even in an adult, must occur 
rapidly and efficiently for a grafted neo-organ to thrive after 
implantation.
127 Moreover, special measures may be nece-
ssary to ensure survival of grafted tissue during the initial 
period after implantation, until a functional vascular bed 
is in place. Currently, three types of strategies have been 
devised to solve the oxygen supply problem.
　The first strategy involves the use of mechanical or che-
mical sources of oxygen that can support the construct be-
fore and immediately after implantation, until the neo-
vascularization process is completed and can provide the 
neo-organ with sufficient blood circulation. An intra-tissue 
perfusion system utilizing an array of micro-needles to de-
liver oxygen and nutrients and eliminate waste enhances 
the viability and functionality of thick (1 mm) slices of liver 
tissue in vitro and might facilitate in vivo grafting.
128 In ad-
dition, the use of oxygen-carrying molecules such as per-
fluorocarbons could promote the function of cells in culture 
and of encapsulated cells and organ constructs implanted 
into animals.
129-130 Our laboratory recently showed that a 
PLGA film incorporating an oxygen-generating system 
(sodium percarbonate) could prevent the necrosis of ische-
mic tissue over several days in vivo.
131 We hope to develop 
such novel scaffold materials further to support the surviv-
al of large, complex organ constructs in the initial period 
after implantation.
　Second, “prevascularization” strategies aim to generate 
neo-organs engineered with a preexisting channel struc-
ture to facilitate the generation of a competent vascular 
network.
130,132 To accomplish this, endothelial lineage cells 
can be pre-seeded into the channels or may be recruited in 
vivo by using biochemical signals that are embedded in or 
released by the scaffold. However, there is still the question 
of how to create channels in a way that will be interpreted 
as a natural vascular network by the body. One solution 
would be to employ decellularized tissue as the scaffold. A 
recent study demonstrated that perfusion of an entire 
heart with detergents yields an acellular structure in 
which the native vascular channels remain intact.
133 We 
independently devised perfusion-decellularization tech-
nology using liver tissue and have found that the vascular 
tree of the whole organ scaffold remains patent and can be 
repopulated with large numbers of endothelial cells.
134 
Alternatively, several technologies can be used to manu-
facture scaffolds with preformed channels, potentially 
with cells incorporated, designed to promote neo-vascula-
rization. For example, laser guided “writing” was used to 
pattern endothelial cells and promote their aggregation in-
to tubular vessels.
135 Similarly, ink-jet-based bioprinting 
of cells and biomaterials by thermal ink jet technology can 9
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provide remarkable control of the fine structure of engi-
neered tissues, including the generation of intricate vessel 
networks.
136 We have used layer-by-layer ink jet printing 
to produce three-dimensional constructs containing endo-
thelial cells and showed that these develop functional mi-
crovascularization when implanted in vivo, as assessed by 
magnetic resonance imaging.
137 Electrospinning of living 
cells with biomaterials offers similar potential to fabricate 
organ structures with pre-patterned vessels.
138 Mathe-
matical modeling of scaffolds designed to contain a preex-
isting arteriovenous loop shows how the provision of an 
oxygen source within the scaffold can dynamically support 
further neo-vascularization and tissue development.
139
　Third, it is well established that growth factors such as 
VEGF and FGF can promote vascularization in engineered 
tissues.
140 Recent efforts have extended this approach by 
incorporating additional pro-angiogenic molecules into 
scaffolds, such as organ-specific ECM from liver to support 
sinusoidal endothelial cells.
141 Synthetic biomaterials de-
signed to provide signals normally presented by the ECM 
will complement, and may eventually supersede, the use 
of the native molecules.
142
　Finally, several of the clinical trials involving bioengi-
neered products have been placed on hold because of the 
costs involved with the specific technology. With a bioengi-
neered product, costs are usually high because of the bio-
logical nature of the therapies involved, and as with any 
therapy, the cost that the medical health care system can 
allow for a specific technology is limited. Therefore, the 
costs of bioengineered products have to be lowered before 
they can have an impact clinically. This is currently being 
addressed for multiple tissue-engineered technologies. As 
the technologies advance over time, and the volume of the 
application is considered, costs will naturally decrease.
SUMMARY AND CONCLUSION
　Regenerative medicine efforts are currently underway 
experimentally for virtually every type of tissue and organ 
within the human body. As regenerative medicine incorpo-
rates the fields of tissue engineering, cell biology, nuclear 
transfer, and materials science, personnel who have mas-
tered the techniques of cell harvest, culture, expansion, 
transplantation, and polymer design are essential for the 
successful application of these technologies to extend hu-
man life. Various tissues are at different stages of develop-
ment, with some already being used clinically, a few in pre-
clinical trials, and some in the discovery stage. Recent prog-
ress suggests that engineered tissues may have an expanded 
clinical applicability in the future and may represent a via-
ble therapeutic option for those who would benefit from the 
life-extending benefits of tissue replacement or repair.
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